Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen

Posted by Francis Steltz on Sep 29th, 2026

Wall Street Zen downgraded shares of Opus Genetics (NASDAQ:IRD – Free Report) from a hold rating to a sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Several other equities research analysts have also weighed in on the company. Royal Bank Of Canada lowered their price objective on Opus Genetics from $10.00 to $9.00 and set an “outperform” rating on the stock in a research note on Friday, August 7th. Zacks Research raised Opus Genetics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Citizens Jmp reiterated a “market outperform” rating and issued a $11.00 price target on shares of Opus Genetics in a research report on Monday, June 15th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Opus Genetics in a report on Wednesday, September 9th. Finally, TD Cowen initiated coverage on shares of Opus Genetics in a research note on Wednesday, July 29th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Opus Genetics has a consensus rating of “Moderate Buy” and a consensus price target of $11.92.

Read Our Latest Stock Analysis on IRD

Opus Genetics Stock Performance

Shares of Opus Genetics stock opened at $5.05 on Friday. The firm has a market cap of $417.38 million, a P/E ratio of -3.74 and a beta of 0.58. The firm’s 50-day simple moving average is $4.23 and its 200-day simple moving average is $4.41. Opus Genetics has a twelve month low of $1.50 and a twelve month high of $7.07.

Opus Genetics (NASDAQ:IRD – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $2.63 million. Opus Genetics had a negative net margin of 1,091.82% and a negative return on equity of 338.88%. On average, equities analysts forecast that Opus Genetics will post -0.96 earnings per share for the current fiscal year.

Insider Activity at Opus Genetics

In related news, CFO Robert E. Gagnon sold 28,000 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $4.54, for a total transaction of $127,120.00. Following the completion of the sale, the chief financial officer directly owned 556,375 shares of the company’s stock, valued at $2,525,942.50. This trade represents a 4.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO George Magrath sold 9,475 shares of Opus Genetics stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total value of $27,951.25. Following the completion of the transaction, the chief executive officer owned 1,731,869 shares of the company’s stock, valued at approximately $5,109,013.55. The trade was a 0.54% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 57,331 shares of company stock worth $213,749 over the last three months. 11.70% of the stock is owned by company insiders.

Institutional Trading of Opus Genetics

Several large investors have recently made changes to their positions in the business. Opaleye Management Inc. raised its holdings in shares of Opus Genetics by 0.4% in the second quarter. Opaleye Management Inc. now owns 1,125,000 shares of the company’s stock valued at $4,624,000 after buying an additional 5,000 shares during the last quarter. Seven Fleet Capital Management LP grew its holdings in Opus Genetics by 6.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 143,137 shares of the company’s stock worth $588,000 after acquiring an additional 8,895 shares during the last quarter. Engineers Gate Manager LP bought a new stake in Opus Genetics during the 2nd quarter worth about $50,000. Stoneridge Investment Partners LLC acquired a new stake in Opus Genetics in the 2nd quarter valued at about $47,000. Finally, State of Wyoming acquired a new stake in Opus Genetics in the 2nd quarter valued at about $65,000. Institutional investors own 14.97% of the company’s stock.

About Opus Genetics

(Get Free Report)

Opus Genetics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs), a group of rare genetic disorders that can cause progressive vision loss or blindness. The company aims to address conditions for which treatment options are limited or unavailable by developing therapies designed to correct or replace disease-causing genetic defects in retinal cells.

Opus Genetics’ pipeline includes investigational programs for genetically defined retinal disorders, including rhodopsin-associated autosomal dominant retinitis pigmentosa and BEST1-related retinal disease.